إعلان
إعلان
FATE
Fate Therapeutics, Inc.
1.06
USDبرعاية
-0.05
-4.05%
٠٨ يناير, ١٥:٤٠ UTC -5
مغلق
بعد الإغلاق
1.07
+0.01
+0.94%
تقارير أرباح FATE
النسبة الإيجابية المفاجئة
FATE تفوق 22 من 40 آخر التقديرات.
55%
التقرير التالي
بيانات التقرير القادم
٠٣ مارس ٢٠٢٦
Estimate for Q4 25 (Revenue/ EPS)
$1.21M
/-$0.27
التغير الضمني من Q3 25 (Revenue/ EPS)
-30.52%
/--
التغير الضمني من Q4 24 (Revenue/ EPS)
-34.96%
/-38.64%
Fate Therapeutics, Inc. earnings per share and revenue
On ١٣ نوفمبر ٢٠٢٥, FATE reported earnings of -0.27 USD per share (EPS) for Q3 25, beating the estimate of -0.29 USD, resulting in a 9.06% surprise. Revenue reached 1.74 مليون, compared to an expected 1.57 مليون, with a 11.20% difference. The market reacted with a -4.59% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 15 المحللين forecast an EPS of -0.27 USD, with revenue projected to reach 1.21 مليون USD, implying an زيادة of 0.00% EPS, and نقصان of -30.52% in Revenue from the last quarter.
الأسئلة الشائعة
What were Fate Therapeutics, Inc.'s earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Fate Therapeutics, Inc. reported EPS of -$0.27, beating estimates by 9.06%, and revenue of $1.74M, 11.2% above expectations.
How did the market react to Fate Therapeutics, Inc.'s Q3 2025 earnings?
The stock price moved down -4.59%, changed from $1.04 before the earnings release to $0.99 the day after.
When is Fate Therapeutics, Inc. expected to report next?
The next earning report is scheduled for ٠٣ مارس ٢٠٢٦.
What are the forecasts for Fate Therapeutics, Inc.'s next earnings report?
Based on 15
المحللين, Fate Therapeutics, Inc. is expected to report EPS of -$0.27 and revenue of $1.21M for Q4 2025.
Which companies are reporting earnings today?
شيك FXEmpire's Earnings Calendar for today's list of reporting companies.
إعلان